Загрузка...
Facts and Hopes in Immunotherapy of Lymphoma and Myeloma
Immune checkpoint blockade has driven a revolution in modern oncology, and robust drug development of immune checkpoint inhibitors is underway in both solid tumors and hematologic malignancies. High response rates to programmed cell death 1 (PD-1) blockade using nivolumab or pembrolizumab in classic...
Сохранить в:
| Опубликовано в: : | Clin Cancer Res |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5844779/ https://ncbi.nlm.nih.gov/pubmed/28899972 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0539 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|